Inovio Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 279.82 million compared to USD 303.66 million a year ago. Basic loss per share from continuing operations was USD 1.17 compared to USD 1.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.13 USD | -0.30% | -2.50% | +65.52% |
05-14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.52% | 261M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022